Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.
Arcellx, Inc. developed cell therapies and immunotherapies for cancer and other incurable diseases, with company news centered on anitocabtagene autoleucel, or anito-cel, an investigational BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Coverage included clinical data from the iMMagine program, scientific presentations on the D-Domain binder, and collaboration activity with Kite, a Gilead company.
Arcellx became a wholly owned subsidiary of Gilead Sciences after the completed acquisition in 2026, and its common stock was delisted from the Nasdaq Global Select Market. Later company developments therefore include the completed transaction, shareholder-related deal coverage, capital-structure matters, and public-company status changes.
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology firm focused on innovative immunotherapies for cancer, announced its participation in two upcoming investor conferences. The Guggenheim Oncology Conference will feature a fireside chat on February 9, 2023, at 11:20 a.m. ET, while the SVB Securities Global Biopharma Conference will be held virtually on February 16, 2023, at 3:00 p.m. ET. Live webcasts will be available on Arcellx's website with replays archived for 30 days. Arcellx is advancing its lead candidate, CART-ddBCMA, in pivotal trials for multiple myeloma, supported by several FDA designations.
On January 29, 2023, Kite, a Gilead company (NASDAQ: GILD), and Arcellx (NASDAQ: ACLX) announced the completion of a global strategic collaboration to co-develop and co-commercialize CART-ddBCMA, a late-stage product candidate for treating relapsed or refractory multiple myeloma. Currently in a Phase 2 pivotal trial, CART-ddBCMA leverages a novel synthetic binder technology. The collaboration will allow Kite to commercialize the therapy outside the U.S., while both companies will advance the asset in the U.S. This partnership aims to address the urgent need for effective therapies in treating multiple myeloma, an incurable cancer for most patients.
Kite and Arcellx have announced a global collaboration to co-develop the CART-ddBCMA therapy for relapsed or refractory multiple myeloma. Kite will provide an upfront payment of $225 million and a $100 million equity investment. The companies will share development and commercialization costs, splitting U.S. profits 50/50. The partnership aims to address the significant unmet need in multiple myeloma treatment.
The transaction is expected to close in Q1 2023 and may reduce Gilead's EPS by approximately $0.16. The collaboration capitalizes on Kite's leadership in cell therapy and Arcellx's innovative approach.
Arcellx (NASDAQ: ACLX) reported promising long-term results from the CART-ddBCMA Phase 1 expansion trial, where 100% of patients achieved an overall response rate. Of 38 evaluable patients, 71% reached complete or stringent complete response (CR/sCR). No severe toxicities were noted at the recommended Phase 2 dose of 115 million CAR+ T cells. Additionally, the company initiated the iMMagine-1 Phase 2 trial and the Phase 1 trial for ACLX-002 targeting acute myeloid leukemia and myelodysplastic syndromes. The developments indicate a strong commitment to advancing innovative cancer therapies.
Arcellx and Kite, a Gilead Company, have entered into a strategic collaboration to co-develop and commercialize CART-ddBCMA, a late-stage cell therapy for relapsed or refractory multiple myeloma. Arcellx will receive an upfront payment of $225M, a $100M equity investment, and potential contingent payments up to $3.9B. The companies will share U.S. profits 50/50 while Arcellx earns royalties on sales outside the U.S. The collaboration aims to accelerate patient access to innovative therapies.
Arcellx, Inc. (NASDAQ: ACLX) reported its third-quarter 2022 financial results, highlighting the initiation of the pivotal iMMagine-1 Phase 2 study for CART-ddBCMA aimed at treating relapsed multiple myeloma. The company has $280.8 million in cash, sufficient to fund operations for the next 12 months. R&D expenses surged to $83.5 million, primarily due to a one-time $63.1 million non-cash expense related to Lonza manufacturing services. The net loss for the quarter was $92.9 million, marking a significant increase from $17.1 million in Q3 2021.
Arcellx, Inc. (ACLX) announced significant developments in its Q2 2022 financial results and business highlights. The company completed a public offering raising $128.8 million and presented promising data from its CART-ddBCMA Phase 1 trial at the ASCO Annual Meeting, reporting a 100% overall response rate. Cash reserves as of June 30, 2022, stood at $307 million. However, the company incurred a net loss of $32.1 million, up from $15.9 million a year earlier, driven largely by increased R&D expenses.
Arcellx, Inc. (NASDAQ: ACLX) has appointed Maryam Abdul-Kareem, J.D., as General Counsel, bringing extensive experience in the biopharmaceutical industry from her previous roles at Kinnate Biopharma and AstraZeneca. Abdul-Kareem's responsibilities will include overseeing legal, contracts, and compliance matters as the company scales its operations. CEO Rami Elghandour emphasized her leadership skills and commitment to diversity as vital for the company’s growth.
Arcellx is focused on developing innovative immunotherapies for cancer and related diseases, including its lead candidate CART-ddBCMA.
Arcellx, Inc. (NASDAQ: ACLX) has successfully closed its upsized public offering, raising $128.8 million through the sale of 8,050,000 shares of common stock at $16.00 per share. This includes the full exercise of an option by underwriters to purchase an additional 1,050,000 shares. The offering, which was registered with the SEC and became effective on June 15, 2022, aims to advance Arcellx's innovative immunotherapies, including CART-ddBCMA for multiple myeloma and ARC-SparX for various cancers.
Arcellx, Inc. (NASDAQ: ACLX) announced a follow-on public offering of 7,000,000 shares at $16.00 per share, raising $112 million in gross proceeds. This offering is an increase from the initial size of 4,000,000 shares. Underwriters have a 30-day option to purchase an additional 1,050,000 shares. The offering is set to close on June 21, 2022. BofA Securities, SVB Securities, William Blair, and Canaccord Genuity are acting as joint book-running managers.